Company / R&D Expense
Decoy Therapeutics Inc. R&D Expense History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$8.5M
FY2022
5-year range
$1.3M / $20.4M
FY2018-FY2022
Trend
+23.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 3 consecutive years, from $1M in FY2019 to $9M in FY2022.
Based on SEC 10-K filings.
$9M in FY2022 with a 5-year CAGR of -7.7%.
Improved from $4M to $9M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +87.9%
- 5-Year CAGR
- -7.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Decoy Therapeutics Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of -7.7%, indicating a declining trend.
- In FY2022, r&d expense increased 23.6% year-over-year.
- Peak r&d expense was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $8.5M | +23.6% |
| FY2021 | $6.9M | +72.0% |
| FY2020 | $4.0M | +212.1% |
| FY2019 | $1.3M | -93.7% |
| FY2018 | $20.4M | +59.8% |
| FY2017 | $12.7M | +218.4% |
| FY2016 | $4.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026